<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00989</drugbank-id>
  <drugbank-id>APRD00321</drugbank-id>
  <name>Rivastigmine</name>
  <description>Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.</description>
  <cas-number>123441-03-2</cas-number>
  <unii>PKI06M3IW0</unii>
  <average-mass>250.3367</average-mass>
  <monoisotopic-mass>250.168127958</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1547</ref-id>
        <pubmed-id>12369954</pubmed-id>
        <citation>Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25.</citation>
      </article>
      <article>
        <ref-id>A1548</ref-id>
        <pubmed-id>10066203</pubmed-id>
        <citation>Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8.</citation>
      </article>
      <article>
        <ref-id>A1549</ref-id>
        <pubmed-id>15336465</pubmed-id>
        <citation>Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther. 2004 Jul;26(7):980-90.</citation>
      </article>
      <article>
        <ref-id>A1550</ref-id>
        <pubmed-id>11568422</pubmed-id>
        <citation>Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 1998;11(4):211-216.</citation>
      </article>
      <article>
        <ref-id>A1551</ref-id>
        <pubmed-id>15590953</pubmed-id>
        <citation>Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2509-18.</citation>
      </article>
      <article>
        <ref-id>A1552</ref-id>
        <pubmed-id>19370562</pubmed-id>
        <citation>Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2.</citation>
      </article>
      <article>
        <ref-id>A1553</ref-id>
        <pubmed-id>19470293</pubmed-id>
        <citation>Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85.</citation>
      </article>
      <article>
        <ref-id>A1554</ref-id>
        <pubmed-id>14587496</pubmed-id>
        <citation>Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Venkata Naga Brahmeswara Rao Mandava, Venkata Reddy Vajrala, Ganesh Varanasi, Vijay Kumar Adla, Mukund Reddy Jambula, Vijaypal Reddy Kanumathi Reddy, "PREPARATION OF RIVASTIGMINE AND ITS SALTS." U.S. Patent US20080255383, issued October 16, 2008.</synthesis-reference>
  <indication>For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.</indication>
  <pharmacodynamics>Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.</pharmacodynamics>
  <mechanism-of-action>Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.</mechanism-of-action>
  <toxicity/>
  <metabolism>Rivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.</metabolism>
  <absorption/>
  <half-life>1.5 hours</half-life>
  <protein-binding>40%</protein-binding>
  <route-of-elimination>Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.</route-of-elimination>
  <volume-of-distribution>* 1.8 to 2.7 L/kg</volume-of-distribution>
  <clearance>* renal cl=2.1-2.8 L/hr</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenoxy compounds. These are aromatic compounds contaning a phenoxy group.</description>
    <direct-parent>Phenoxy compounds</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Phenoxy compounds</subclass>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Carbamate esters</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic carbonic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Carbamic acid ester</substituent>
    <substituent>Carbonic acid derivative</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001252</drugbank-id>
      <name>Rivastigmine tartrate</name>
      <unii>9IY2357JPE</unii>
      <cas-number>129101-54-8</cas-number>
      <inchikey>GWHQHAUAXRMMOT-MBANBULQSA-N</inchikey>
      <average-mass>400.428</average-mass>
      <monoisotopic-mass>400.18456587</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate</synonym>
    <synonym language="english" coder="">m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate</synonym>
    <synonym language="spanish" coder="">Rivastigmina</synonym>
    <synonym language="english" coder="inn/usan">Rivastigmine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Act Rivastigmine Patch 10</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02423537</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Rivastigmine Patch 5</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02423529</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-rivastigmine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02336715</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-rivastigmine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02336723</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-rivastigmine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02336731</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-rivastigmine</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02336758</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-rivastigmine</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427567</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-rivastigmine</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427575</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-rivastigmine</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427583</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-rivastigmine</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427591</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-rivastigmine</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02307685</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-rivastigmine</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02307693</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-rivastigmine</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02307707</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-rivastigmine</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02307715</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/001</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/002</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/003</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/004</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/005</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/006</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/007</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/008</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/009</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/010</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/011</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/012</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/013</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/ml</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/014</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/015</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/016</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/017</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/018</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/ml</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/019</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/020</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/021</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/022</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/023</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/024</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/025</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/026</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/027</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/028</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/029</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/030</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/031</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/032</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/033</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000169</ema-product-code>
      <ema-ma-number>EU/1/98/066/034</ema-ma-number>
      <started-marketing-on>1998-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24[USP'U]</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5954</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24[USP'U]</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5839</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5339</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24[USP'U]</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0639</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-07</started-marketing-on>
      <ended-marketing-on>2018-06-15</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0339</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-01</started-marketing-on>
      <ended-marketing-on>2006-08-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0503</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0323</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242116</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242117</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245240</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon 1.5 mg</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242115</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon Patch 10</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302853</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon Patch 15</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02432803</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exelon Patch 5</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302845</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Rivastigmine</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485362</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Rivastigmine</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485370</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Rivastigmine</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp Rivastigmine</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485397</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Med-rivastigmine</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401614</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Med-rivastigmine</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401622</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Med-rivastigmine</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401649</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Med-rivastigmine</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401630</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-rivastigmine</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02406985</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-02</started-marketing-on>
      <ended-marketing-on>2017-06-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-rivastigmine</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02406993</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-02</started-marketing-on>
      <ended-marketing-on>2017-06-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-rivastigmine</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02407000</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-02</started-marketing-on>
      <ended-marketing-on>2017-06-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-rivastigmine</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02407019</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-02</started-marketing-on>
      <ended-marketing-on>2017-06-19</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-rivastigmine</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332809</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2016-11-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-rivastigmine</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332817</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2016-11-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-rivastigmine</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332825</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2016-11-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-rivastigmine</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02332833</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2016-11-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-rivastigmine Patch 10</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02423421</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-rivastigmine Patch 5</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02423413</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/001</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/002</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/003</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/004</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/005</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/006</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/007</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/008</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/009</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/010</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/011</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/012</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/013</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/014</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/015</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/016</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/017</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/018</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/019</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/020</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/021</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/022</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/023</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/024</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/025</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/026</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/027</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/028</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/029</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/030</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/031</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/032</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/033</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/034</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/035</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/036</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/037</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/038</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/039</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/040</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/041</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/042</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/043</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/044</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/045</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/046</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/047</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/048</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/049</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nimvastid</name>
      <labeller>Krka, D.D., Novo Mesto</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001029</ema-product-code>
      <ema-ma-number>EU/1/09/525/050</ema-ma-number>
      <started-marketing-on>2009-05-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Novo-rivastigmine</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02305984</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-rivastigmine</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02305992</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-rivastigmine</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306018</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novo-rivastigmine</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306026</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-rivastigmine</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308169</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-rivastigmine</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308177</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-rivastigmine</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308185</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-rivastigmine</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308193</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-rivastigmine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306034</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-rivastigmine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306042</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-rivastigmine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306050</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-rivastigmine</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02306069</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Priva-rivastigmine</name>
      <labeller>Pharmapar Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02490153</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Priva-rivastigmine</name>
      <labeller>Pharmapar Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02490161</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Priva-rivastigmine</name>
      <labeller>Pharmapar Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02490188</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/001</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/002</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/003</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/004</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/005</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/006</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/007</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/008</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/009</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/010</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/011</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/012</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/013</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/ml</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/014</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/015</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/016</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/017</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/018</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/ml</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/019</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/020</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/021</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/022</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/023</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/024</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/025</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/026</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/027</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/028</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/029</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Prometax</name>
      <labeller>Novartis Europharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000255</ema-product-code>
      <ema-ma-number>EU/1/98/092/030</ema-ma-number>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24hours</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Ratio-rivastigmine</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311283</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-rivastigmine</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311291</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-rivastigmine</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311305</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-rivastigmine</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311313</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-02</started-marketing-on>
      <ended-marketing-on>2018-05-18</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70710-1196</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70710-1197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70710-1198</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Zydus Technologies Limited</labeller>
      <ndc-id/>
      <ndc-product-code>51956-0001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Zydus Technologies Limited</labeller>
      <ndc-id/>
      <ndc-product-code>51956-0002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Zydus Technologies Limited</labeller>
      <ndc-id/>
      <ndc-product-code>51956-0003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-825</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA207308</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA207308</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-749</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA207308</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-7304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-7309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-7313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>NDA022083</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Northstar Rx Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>16714-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Northstar Rx Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>16714-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Northstar Rx Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>16714-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA206318</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-9070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA205622</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-9071</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA205622</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-9072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA205622</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02416999</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417006</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417014</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417022</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/001</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/002</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/003</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/004</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/005</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/006</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/007</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/008</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/009</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/010</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/011</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/012</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/013</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/014</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/015</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 1 A Pharma</name>
      <labeller>1 A Pharma Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001181</ema-product-code>
      <ema-ma-number>EU/1/09/585/016</ema-ma-number>
      <started-marketing-on>2009-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/001</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/002</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/003</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/004</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/005</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/006</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/007</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <labeller>3 M Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003824</ema-product-code>
      <ema-ma-number>EU/1/14/911/008</ema-ma-number>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on>2014-09-18</ended-marketing-on>
      <dosage-form>Patch</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/001</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/002</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/003</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/004</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/005</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/006</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/007</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/008</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/009</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/010</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/011</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/012</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/013</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/014</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/015</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Actavis</name>
      <labeller>Actavis Group Ptc Ehf.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002036</ema-product-code>
      <ema-ma-number>EU/1/11/693/016</ema-ma-number>
      <started-marketing-on>2011-06-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/001</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/002</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/003</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/004</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/005</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/006</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/007</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/008</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/009</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/010</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/011</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/012</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/013</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/014</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/015</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001183</ema-product-code>
      <ema-ma-number>EU/1/09/599/016</ema-ma-number>
      <started-marketing-on>2009-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2614</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2616</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-2617</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020823</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-4134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0793</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-19</started-marketing-on>
      <ended-marketing-on>2018-06-07</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Nivagen Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75834-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65691-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-25</started-marketing-on>
      <ended-marketing-on>2017-03-22</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65691-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-25</started-marketing-on>
      <ended-marketing-on>2017-03-22</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65691-016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-25</started-marketing-on>
      <ended-marketing-on>2017-03-22</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharnmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65691-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-25</started-marketing-on>
      <ended-marketing-on>2017-03-22</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>63739-576</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>63739-577</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>63739-578</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Mc Kesson</labeller>
      <ndc-id/>
      <ndc-product-code>63739-579</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207797</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207797</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207797</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207797</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-393</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-394</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-395</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-396</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3221</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3222</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3223</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091072</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-352</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-353</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-354</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Dr. Reddy's Laboratories Limited</labeller>
      <ndc-id/>
      <ndc-product-code>55111-355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077130</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62756-145</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62756-146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62756-147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62756-148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203148</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203148</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203148</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203148</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3209</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3210</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Breckenridge Pharmaceutical, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>51991-793</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Breckenridge Pharmaceutical, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>51991-794</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Breckenridge Pharmaceutical, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>51991-795</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Breckenridge Pharmaceutical, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>51991-796</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>71209-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>71209-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>71209-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Cadila Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>71209-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203844</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-064</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-066</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091689</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-648</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-649</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-650</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-651</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204572</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-550</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077131</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6587</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077129</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate Capsules</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02375729</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate Capsules</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02375737</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate Capsules</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02375745</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine Tartrate Capsules</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02375753</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/001</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/002</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/003</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/004</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/005</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>1.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/006</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/007</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/008</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/009</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/010</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>3 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/011</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/012</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/013</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/014</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/015</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>4.5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/016</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/017</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/018</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/019</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Teva</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001044</ema-product-code>
      <ema-ma-number>EU/1/09/513/020</ema-ma-number>
      <started-marketing-on>2009-04-17</started-marketing-on>
      <ended-marketing-on>2012-09-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>6 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal Patch</name>
      <labeller>Strides Pharma Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479540</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal Patch</name>
      <labeller>Strides Pharma Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479559</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal Patch</name>
      <labeller>Strides Pharma Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479567</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/1</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA204403</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/1</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA204403</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Alvogen Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47781-405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/1</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA204403</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-897</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA209063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-898</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA209063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA209063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Adhexpharma</labeller>
      <ndc-id/>
      <ndc-product-code>72855-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>4.6 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA209063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Adhexpharma</labeller>
      <ndc-id/>
      <ndc-product-code>72855-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>9.5 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA209063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rivastigmine Transdermal System</name>
      <labeller>Adhexpharma</labeller>
      <ndc-id/>
      <ndc-product-code>72855-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch, extended release</dosage-form>
      <strength>13.3 mg/24h</strength>
      <route>Transdermal</route>
      <fda-application-number>ANDA209063</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sandoz Rivastigmine</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02324563</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Rivastigmine</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02324571</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Rivastigmine</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02324598</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Rivastigmine</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02324601</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Rivastigmine Patch 10</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02426307</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Rivastigmine Patch 5</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02426293</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Exelon Patch</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Nimvastid</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Teva</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Actavis</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 3m Health Care Ltd.</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Prometax</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Sandoz</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine 1 A Pharma</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal System</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon 1.5 mg</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Med-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Med-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Med-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Dom-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Dom-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Dom-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Dom-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate Capsules</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate Capsules</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate Capsules</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Tartrate Capsules</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Apo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Apo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Apo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Apo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Med-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Act Rivastigmine Patch 5</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Act Rivastigmine Patch 10</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mint-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mint-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mint-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mint-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Novo-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PMS-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>PHL-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon Patch 5</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon Patch 10</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-rivastigmine Patch 5</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-rivastigmine Patch 10</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Rivastigmine Patch 5</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Rivastigmine Patch 10</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Exelon Patch 15</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Auro-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Auro-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Auro-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Auro-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal Patch</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal Patch</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Rivastigmine Transdermal Patch</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Jamp Rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Priva-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Priva-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
    <mixture>
      <name>Priva-rivastigmine</name>
      <ingredients>Rivastigmine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Atlantic Biologicals Corporation</name>
      <url>http://www.atlanticbiologicals.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Doctor Reddys Laboratories Ltd.</name>
      <url>http://www.drreddys.com</url>
    </packager>
    <packager>
      <name>LTS Lohmann Therapy Systems Corp.</name>
      <url>http://www.ltslohmann.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Sun Pharmaceutical Industries Ltd.</name>
      <url>http://www.sunpharma.com</url>
    </packager>
    <packager>
      <name>Vangard Labs Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Watson Pharmaceuticals</name>
      <url>http://www.watson.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Novartis pharmaceuticals corp</manufacturer>
    <manufacturer generic="true" url="">Dr reddys laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Sun pharmaceutical industries ltd</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Exelon 1.5 mg capsule</description>
      <cost currency="USD">4.81</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Exelon 3 mg capsule</description>
      <cost currency="USD">4.81</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Exelon 4.5 mg capsule</description>
      <cost currency="USD">4.81</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Exelon 6 mg capsule</description>
      <cost currency="USD">4.81</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Exelon 4.6 mg/24hr patch</description>
      <cost currency="USD">8.08</cost>
      <unit>patch</unit>
    </price>
    <price>
      <description>Exelon 9.5 mg/24hr patch</description>
      <cost currency="USD">8.08</cost>
      <unit>patch</unit>
    </price>
    <price>
      <description>Exelon 30 4.6 mg/24hr Patches Box</description>
      <cost currency="USD">252.18</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Exelon 30 9.5 mg/24hr Patches Box</description>
      <cost currency="USD">252.18</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Acyclic</category>
      <mesh-id>D000144</mesh-id>
    </category>
    <category>
      <category>Anti-Dementia Drugs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Bradycardia-Causing Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbamates</category>
      <mesh-id>D002219</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Cholinergic Agents</category>
      <mesh-id>D018678</mesh-id>
    </category>
    <category>
      <category>Cholinesterase Inhibitors</category>
      <mesh-id>D002800</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neuroprotective Agents</category>
      <mesh-id>D018696</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Parasympathomemetic (Cholinergic) Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phenylcarbamates</category>
      <mesh-id>D048448</mesh-id>
    </category>
    <category>
      <category>Protective Agents</category>
      <mesh-id>D020011</mesh-id>
    </category>
    <category>
      <category>Psychoanaleptics</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>1.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>1.5 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>3 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>4.5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>4.5 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>6 mg</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>13.3 mg/24hours</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>4.6 mg/24hours</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>9.5 mg/24hours</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>13.3 mg/24h</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>4.6 mg/24[USP'U]</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>4.6 mg/24h</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>9.5 mg/24h</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>9.5 mg/24[USP'U]</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>2 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>2 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>1.5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>3 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>4.5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>6 mg</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>13.3 mg/24h</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>4.6 mg/24h</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Transdermal</route>
      <strength>9.5 mg/24h</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>6 mg/1</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>13.3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>4.6 mg/1</strength>
    </dosage>
    <dosage>
      <form>Patch, extended release</form>
      <route>Transdermal</route>
      <strength>9.5 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N06DA03">
      <level code="N06DA">Anticholinesterases</level>
      <level code="N06D">ANTI-DEMENTIA DRUGS</level>
      <level code="N06">PSYCHOANALEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>12:04.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00989.pdf?1265922808</fda-label>
  <patents>
    <patent>
      <number>4948807</number>
      <country>United States</country>
      <approved>1990-08-14</approved>
      <expires>2012-08-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2315784</number>
      <country>Canada</country>
      <approved>2006-06-27</approved>
      <expires>2019-01-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6335031</number>
      <country>United States</country>
      <approved>2002-01-01</approved>
      <expires>2019-01-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6316023</number>
      <country>United States</country>
      <approved>2001-11-13</approved>
      <expires>2019-01-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>Rivastigmine may increase the bradycardic activities of Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09083</drugbank-id>
      <name>Ivabradine</name>
      <description>Rivastigmine may increase the bradycardic activities of Ivabradine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>Ruxolitinib may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Esmolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Betaxolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Metoprolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Atenolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Timolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Sotalol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Propranolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Labetalol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Bisoprolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Alprenolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Pindolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Carvedilol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>Propafenone may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Acebutolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Nadolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Bevantolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Practolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Penbutolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Oxprenolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>Dexpropranolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Celiprolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>Nebivolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Bufuralol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Bopindolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Bupranolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Indenolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Befunolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Arotinolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>Levobetaxolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>Talinolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Anisodamine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Landiolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Bucindolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>Esatenolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>Cloranolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>Mepindolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>Epanolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>Tertatolol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Succinylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Ephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05875</drugbank-id>
      <name>Sar9, Met (O2)11-Substance P</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Moxisylyte.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04250</drugbank-id>
      <name>Butyrylthiocholine</name>
      <description>Rivastigmine may increase the neuromuscular blocking activities of Butyrylthiocholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The therapeutic efficacy of Tramadol can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The therapeutic efficacy of Trospium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The therapeutic efficacy of Butabarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Butalbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The therapeutic efficacy of Benzatropine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Disopyramide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The therapeutic efficacy of Talbutal can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The therapeutic efficacy of Ipratropium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The therapeutic efficacy of Methadone can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Olanzapine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Metixene can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The therapeutic efficacy of Buclizine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Clozapine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The therapeutic efficacy of Doxylamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Procyclidine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Profenamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Secobarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Promazine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Metharbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The therapeutic efficacy of Amoxapine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The therapeutic efficacy of Atropine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Thiopental can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The therapeutic efficacy of Nicardipine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Paroxetine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The therapeutic efficacy of Procaine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Isoflurane can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The therapeutic efficacy of Clidinium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Propiomazine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The therapeutic efficacy of Propantheline can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Biperiden can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Flupentixol can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The therapeutic efficacy of Cocaine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Amantadine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The therapeutic efficacy of Maprotiline can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Methantheline can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The therapeutic efficacy of Cycrimine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The therapeutic efficacy of Desloratadine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The therapeutic efficacy of Tolterodine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Promethazine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Pentolinium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The therapeutic efficacy of Flavoxate can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The therapeutic efficacy of Desipramine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The therapeutic efficacy of Chloroprocaine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Escitalopram can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The therapeutic efficacy of Diphenidol can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Fenoterol can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Amobarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The therapeutic efficacy of Butobarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The therapeutic efficacy of Heptabarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The therapeutic efficacy of Tiotropium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Barbital can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The therapeutic efficacy of Barbituric acid derivative can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The therapeutic efficacy of Solifenacin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The therapeutic efficacy of Isopropamide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The therapeutic efficacy of Gantacurium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Pizotifen can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The therapeutic efficacy of Dimetindene can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The therapeutic efficacy of Agmatine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The therapeutic efficacy of Aclidinium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Dexetimide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The therapeutic efficacy of Benactyzine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The therapeutic efficacy of Trimebutine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The therapeutic efficacy of Dosulepin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The therapeutic efficacy of Imidafenacin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The therapeutic efficacy of Revefenacin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The therapeutic efficacy of Oxitropium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Propiverine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Batefenterol can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The therapeutic efficacy of Mebeverine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The therapeutic efficacy of Tropatepine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The therapeutic efficacy of Prifinium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The therapeutic efficacy of Piperidolate can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The therapeutic efficacy of Benzilone can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The therapeutic efficacy of Difemerine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The therapeutic efficacy of Mazaticol can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The therapeutic efficacy of Otilonium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The therapeutic efficacy of Emepronium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The therapeutic efficacy of Poldine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The therapeutic efficacy of Bevonium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The therapeutic efficacy of Rociverine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The therapeutic efficacy of Bornaprine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The therapeutic efficacy of Etanautine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The therapeutic efficacy of Tiemonium iodide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The therapeutic efficacy of Penthienate can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The therapeutic efficacy of Diphemanil can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The therapeutic efficacy of Camylofin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The therapeutic efficacy of Fenpiverinium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The therapeutic efficacy of Emetonium iodide can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The therapeutic efficacy of Timepidium can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The therapeutic efficacy of Terfenadine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The therapeutic efficacy of Imipramine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The therapeutic efficacy of Darifenacin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Quinidine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The therapeutic efficacy of Doxepin can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Quetiapine can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00411</drugbank-id>
      <name>Carbamoylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Carbamoylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01019</drugbank-id>
      <name>Bethanechol</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Bethanechol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Varenicline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03128</drugbank-id>
      <name>Acetylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Acetylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04365</drugbank-id>
      <name>Arecoline</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Arecoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05137</drugbank-id>
      <name>Lobeline</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05152</drugbank-id>
      <name>NGX267</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with NGX267.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with GTS-21.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06709</drugbank-id>
      <name>Methacholine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Methacholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07720</drugbank-id>
      <name>Epibatidine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Epibatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15357</drugbank-id>
      <name>Xanomeline</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Xanomeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Cevimeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01085</drugbank-id>
      <name>Pilocarpine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Pilocarpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>Octreotide may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>Midodrine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Pregabalin may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>Trimethadione may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>Nimodipine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Bendroflumethiazide may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>Cinnarizine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Dexmedetomidine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>Magnesium sulfate may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Galantamine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>Tizanidine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>Sufentanil may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>Levomenthol may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>Donepezil may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>Remifentanil may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>Zonisamide may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Methyldopa may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Rivastigmine may increase the bradycardic activities of Guanfacine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>Rivastigmine may increase the bradycardic activities of Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>Rivastigmine may increase the bradycardic activities of Bretylium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>Rivastigmine may increase the bradycardic activities of Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Rivastigmine may increase the bradycardic activities of Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>Rivastigmine may increase the bradycardic activities of Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>Rivastigmine may increase the bradycardic activities of Cyclandelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>Rivastigmine may increase the bradycardic activities of Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Rivastigmine may increase the bradycardic activities of Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04897</drugbank-id>
      <name>Lucinactant</name>
      <description>Rivastigmine may increase the bradycardic activities of Lucinactant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>Rivastigmine may increase the bradycardic activities of Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>Rivastigmine may increase the bradycardic activities of Seletracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>Rivastigmine may increase the bradycardic activities of Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>Rivastigmine may increase the bradycardic activities of Lacosamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>Rivastigmine may increase the bradycardic activities of Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06415</drugbank-id>
      <name>Calfactant</name>
      <description>Rivastigmine may increase the bradycardic activities of Calfactant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>Rivastigmine may increase the bradycardic activities of Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>Rivastigmine may increase the bradycardic activities of Pasireotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06761</drugbank-id>
      <name>Beractant</name>
      <description>Rivastigmine may increase the bradycardic activities of Beractant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>Rivastigmine may increase the bradycardic activities of Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Rivastigmine may increase the bradycardic activities of Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Rivastigmine may increase the bradycardic activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>Rivastigmine may increase the bradycardic activities of Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>Rivastigmine may increase the bradycardic activities of Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>Rivastigmine may increase the bradycardic activities of Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>Rivastigmine may increase the bradycardic activities of Pinaverium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09113</drugbank-id>
      <name>Poractant alfa</name>
      <description>Rivastigmine may increase the bradycardic activities of Poractant alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>Rivastigmine may increase the bradycardic activities of Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Aranidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Azelnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Darodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Niludipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>Rivastigmine may increase the bradycardic activities of Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Rivastigmine may increase the bradycardic activities of Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Rivastigmine may increase the bradycardic activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>Rivastigmine may increase the bradycardic activities of Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>Rivastigmine may increase the bradycardic activities of Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>Rivastigmine may increase the bradycardic activities of Bencyclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>Rivastigmine may increase the bradycardic activities of Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>Rivastigmine may increase the bradycardic activities of Lidoflazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Rivastigmine may increase the bradycardic activities of Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>Rivastigmine may increase the bradycardic activities of Caroverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>Rivastigmine may increase the bradycardic activities of Fish oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>Rivastigmine may increase the bradycardic activities of Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>Rivastigmine may increase the bradycardic activities of Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>Rivastigmine may increase the bradycardic activities of Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>Rivastigmine may increase the bradycardic activities of Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isradipine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>Diltiazem may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>Amlodipine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Nisoldipine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>Lercanidipine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>Clonidine may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>Ethosuximide may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>Verapamil may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>Alfentanil may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>Fentanyl may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>Loperamide may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Rivastigmine may increase the bradycardic activities of Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>Rivastigmine may increase the bradycardic activities of Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>Rivastigmine may increase the bradycardic activities of Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>Rivastigmine may increase the bradycardic activities of Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>Rivastigmine may increase the bradycardic activities of Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Rivastigmine may increase the bradycardic activities of Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>Rivastigmine may increase the bradycardic activities of WIN 55212-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>Rivastigmine may decrease the neuromuscular blocking activities of Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of adverse effects can be increased when Rivastigmine is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>Lasmiditan may increase the bradycardic activities of Rivastigmine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.45</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.04e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.41</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>exelon</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>250.3367</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>250.168127958</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H22N2O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>XSVMFMHYUFZWBK-NSHDSACASA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>32.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>73.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>28.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>logP</kind>
      <value>2.3</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11987</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>8874</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>77991</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507452</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C11766</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03822</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>70377</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>11682</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA451262</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000149</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Rivastigmine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL636</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/rivastig.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/rivastigmine.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000426</id>
      <name>Acetylcholinesterase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12242</ref-id>
            <pubmed-id>10587286</pubmed-id>
            <citation>Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, Schmidt D, Mancione LC, Parris WC, Ebert MH: Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999 Dec;19(6):513-21.</citation>
          </article>
          <article>
            <ref-id>A12243</ref-id>
            <pubmed-id>10673128</pubmed-id>
            <citation>Goldblum D, Garweg JG, Bohnke M: Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits. J Ocul Pharmacol Ther. 2000 Feb;16(1):29-35.</citation>
          </article>
          <article>
            <ref-id>A12244</ref-id>
            <pubmed-id>10713582</pubmed-id>
            <citation>Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J: Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry. 2000 Mar;15(3):242-7.</citation>
          </article>
          <article>
            <ref-id>A5399</ref-id>
            <pubmed-id>11078030</pubmed-id>
            <citation>Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1.</citation>
          </article>
          <article>
            <ref-id>A12245</ref-id>
            <pubmed-id>11139819</pubmed-id>
            <citation>Gottwald MD, Rozanski RI: Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs. 1999 Oct;8(10):1673-1682.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A1552</ref-id>
            <pubmed-id>19370562</pubmed-id>
            <citation>Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2.</citation>
          </article>
          <article>
            <ref-id>A1553</ref-id>
            <pubmed-id>19470293</pubmed-id>
            <citation>Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85.</citation>
          </article>
          <article>
            <ref-id>A12246</ref-id>
            <pubmed-id>18671661</pubmed-id>
            <citation>Lalli S, Albanese A: Rivastigmine in Parkinson's disease dementia. Expert Rev Neurother. 2008 Aug;8(8):1181-8. doi: 10.1586/14737175.8.8.1181.</citation>
          </article>
          <article>
            <ref-id>A12247</ref-id>
            <pubmed-id>18044073</pubmed-id>
            <citation>Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging. 2007;2(1):17-32.</citation>
          </article>
          <article>
            <ref-id>A1554</ref-id>
            <pubmed-id>14587496</pubmed-id>
            <citation>Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4.</citation>
          </article>
          <article>
            <ref-id>A12248</ref-id>
            <pubmed-id>12636181</pubmed-id>
            <citation>Greig NH, Lahiri DK, Sambamurti K: Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14 Suppl 1:77-91.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P22303" source="Swiss-Prot">
        <name>Acetylcholinesterase</name>
        <general-function>Serine hydrolase activity</general-function>
        <specific-function>Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.</specific-function>
        <gene-name>ACHE</gene-name>
        <locus>7q22</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-31</signal-regions>
        <theoretical-pi>6.24</theoretical-pi>
        <molecular-weight>67795.525</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:108</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ACHE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M55040</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177975</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2465</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P22303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACES_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.7</synonym>
          <synonym>AChE</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000849|Acetylcholinesterase
MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPV
SAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPN
RELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSM
NYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASV
GMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTEL
VACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVG
VVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPE
DPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGY
EIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQ
YVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKN
QFDHYSKQDRCSDL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010296|Acetylcholinesterase (ACHE)
ATGAGGCCCCCGCAGTGTCTGCTGCACACGCCTTCCCTGGCTTCCCCACTCCTTCTCCTC
CTCCTCTGGCTCCTGGGTGGAGGAGTGGGGGCTGAGGGCCGGGAGGATGCAGAGCTGCTG
GTGACGGTGCGTGGGGGCCGGCTGCGGGGCATTCGCCTGAAGACCCCCGGGGGCCCTGTC
TCTGCTTTCCTGGGCATCCCCTTTGCGGAGCCACCCATGGGACCCCGTCGCTTTCTGCCA
CCGGAGCCCAAGCAGCCTTGGTCAGGGGTGGTAGACGCTACAACCTTCCAGAGTGTCTGC
TACCAATATGTGGACACCCTATACCCAGGTTTTGAGGGCACCGAGATGTGGAACCCCAAC
CGTGAGCTGAGCGAGGACTGCCTGTACCTCAACGTGTGGACACCATACCCCCGGCCTACA
TCCCCCACCCCTGTCCTCGTCTGGATCTATGGGGGTGGCTTCTACAGTGGGGCCTCCTCC
TTGGACGTGTACGATGGCCGCTTCTTGGTACAGGCCGAGAGGACTGTGCTGGTGTCCATG
AACTACCGGGTGGGAGCCTTTGGCTTCCTGGCCCTGCCGGGGAGCCGAGAGGCCCCGGGC
AATGTGGGTCTCCTGGATCAGAGGCTGGCCCTGCAGTGGGTGCAGGAGAACGTGGCAGCC
TTCGGGGGTGACCCGACATCAGTGACGCTGTTTGGGGAGAGCGCGGGAGCCGCCTCGGTG
GGCATGCACCTGCTGTCCCCGCCCAGCCGGGGCCTGTTCCACAGGGCCGTGCTGCAGAGC
GGTGCCCCCAATGGACCCTGGGCCACGGTGGGCATGGGAGAGGCCCGTCGCAGGGCCACG
CAGCTGGCCCACCTTGTGGGCTGTCCTCCAGGCGGCACTGGTGGGAATGACACAGAGCTG
GTAGCCTGCCTTCGGACACGACCAGCGCAGGTCCTGGTGAACCACGAATGGCACGTGCTG
CCTCAAGAAAGCGTCTTCCGGTTCTCCTTCGTGCCTGTGGTAGATGGAGACTTCCTCAGT
GACACCCCAGAGGCCCTCATCAACGCGGGAGACTTCCACGGCCTGCAGGTGCTGGTGGGT
GTGGTGAAGGATGAGGGCTCGTATTTTCTGGTTTACGGGGCCCCAGGCTTCAGCAAAGAC
AACGAGTCTCTCATCAGCCGGGCCGAGTTCCTGGCCGGGGTGCGGGTCGGGGTTCCCCAG
GTAAGTGACCTGGCAGCCGAGGCTGTGGTCCTGCATTACACAGACTGGCTGCATCCCGAG
GACCCGGCACGCCTGAGGGAGGCCCTGAGCGATGTGGTGGGCGACCACAATGTCGTGTGC
CCCGTGGCCCAGCTGGCTGGGCGACTGGCTGCCCAGGGTGCCCGGGTCTACGCCTACGTC
TTTGAACACCGTGCTTCCACGCTCTCCTGGCCCCTGTGGATGGGGGTGCCCCACGGCTAC
GAGATCGAGTTCATCTTTGGGATCCCCCTGGACCCCTCTCGAAACTACACGGCAGAGGAG
AAAATCTTCGCCCAGCGACTGATGCGATACTGGGCCAACTTTGCCCGCACAGGGGATCCC
AATGAGCCCCGAGACCCCAAGGCCCCACAATGGCCCCCGTACACGGCGGGGGCTCAGCAG
TACGTTAGTCTGGACCTGCGGCCGCTGGAGGTGCGGCGGGGGCTGCGCGCCCAGGCCTGC
GCCTTCTGGAACCGCTTCCTCCCCAAATTGCTCAGCGCCACCGACACGCTCGACGAGGCG
GAGCGCCAGTGGAAGGCCGAGTTCCACCGCTGGAGCTCCTACATGGTGCACTGGAAGAAC
CAGTTCGACCACTACAGCAAGCAGGATCGCTGCTCAGACCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
          <pfam>
            <identifier>PF08674</identifier>
            <name>AChE_tetra</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>anchored component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basal lamina</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuromuscular junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic cleft</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>collagen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>laminin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acetylcholine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acetylcholine catabolic process in synaptic cleft</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>amyloid precursor protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycerophospholipid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle organ development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, cholinergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter receptor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoblast development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylcholine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein tetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of receptor recycling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0002180</id>
      <name>Cholinesterase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A5399</ref-id>
            <pubmed-id>11078030</pubmed-id>
            <citation>Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1.</citation>
          </article>
          <article>
            <ref-id>A12245</ref-id>
            <pubmed-id>11139819</pubmed-id>
            <citation>Gottwald MD, Rozanski RI: Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs. 1999 Oct;8(10):1673-1682.</citation>
          </article>
          <article>
            <ref-id>A1552</ref-id>
            <pubmed-id>19370562</pubmed-id>
            <citation>Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2.</citation>
          </article>
          <article>
            <ref-id>A1021</ref-id>
            <pubmed-id>16437532</pubmed-id>
            <citation>Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.</citation>
          </article>
          <article>
            <ref-id>A1553</ref-id>
            <pubmed-id>19470293</pubmed-id>
            <citation>Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85.</citation>
          </article>
          <article>
            <ref-id>A13422</ref-id>
            <pubmed-id>19420308</pubmed-id>
            <citation>Smith DA: Treatment of Alzheimer's disease in the long-term-care setting. Am J Health Syst Pharm. 2009 May 15;66(10):899-907. doi: 10.2146/ajhp070622.</citation>
          </article>
          <article>
            <ref-id>A13423</ref-id>
            <pubmed-id>19374459</pubmed-id>
            <citation>Bassil N, Grossberg GT: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs. 2009;23(4):293-307.</citation>
          </article>
          <article>
            <ref-id>A12246</ref-id>
            <pubmed-id>18671661</pubmed-id>
            <citation>Lalli S, Albanese A: Rivastigmine in Parkinson's disease dementia. Expert Rev Neurother. 2008 Aug;8(8):1181-8. doi: 10.1586/14737175.8.8.1181.</citation>
          </article>
          <article>
            <ref-id>A12247</ref-id>
            <pubmed-id>18044073</pubmed-id>
            <citation>Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging. 2007;2(1):17-32.</citation>
          </article>
          <article>
            <ref-id>A1554</ref-id>
            <pubmed-id>14587496</pubmed-id>
            <citation>Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4.</citation>
          </article>
          <article>
            <ref-id>A12248</ref-id>
            <pubmed-id>12636181</pubmed-id>
            <citation>Greig NH, Lahiri DK, Sambamurti K: Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14 Suppl 1:77-91.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P06276" source="Swiss-Prot">
        <name>Cholinesterase</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.</specific-function>
        <gene-name>BCHE</gene-name>
        <locus>3q26.1-q26.2</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>7.47</theoretical-pi>
        <molecular-weight>68417.575</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:983</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>BCHE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M32391</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1311630</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2471</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06276</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CHLE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.8</synonym>
          <synonym>Acylcholine acylhydrolase</synonym>
          <synonym>Butyrylcholine esterase</synonym>
          <synonym>CHE1</synonym>
          <synonym>Choline esterase II</synonym>
          <synonym>Pseudocholinesterase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016706|Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016707|Cholinesterase (BCHE)
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGGTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
          <pfam>
            <identifier>PF08674</identifier>
            <name>AChE_tetra</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope lumen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>catalytic activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>choline binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acetylcholine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>choline metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cocaine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuroblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to alkaloid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to folic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>